Jump to main content
Jump to site search

Issue 5, 2017
Previous Article Next Article

The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M

Author affiliations

Abstract

A graphical abstract is available for this content

Graphical abstract: The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M

Back to tab navigation
Please wait while Download options loads

Publication details

The article was received on 21 Mar 2017, accepted on 21 Mar 2017 and first published on 10 May 2017


Article type: Editorial
DOI: 10.1039/C7MD90012K
Citation: Med. Chem. Commun., 2017,8, 820-822
  •   Request permissions

    The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M

    S. Butterworth, D. A. E. Cross, M. R. V. Finlay, R. A. Ward and M. J. Waring, Med. Chem. Commun., 2017, 8, 820
    DOI: 10.1039/C7MD90012K

Search articles by author